Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by US Bancorp DE

US Bancorp DE trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 8.2% in the 3rd quarter, Holdings Channel reports. The firm owned 7,866 shares of the company’s stock after selling 701 shares during the period. US Bancorp DE’s holdings in Protagonist Therapeutics were worth $354,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Protagonist Therapeutics by 749.2% during the third quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after buying an additional 487 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Protagonist Therapeutics during the first quarter worth about $35,000. Exchange Traded Concepts LLC purchased a new stake in Protagonist Therapeutics during the 3rd quarter valued at about $43,000. CWM LLC raised its holdings in Protagonist Therapeutics by 910.3% in the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after acquiring an additional 1,147 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Protagonist Therapeutics in the 1st quarter worth approximately $69,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now directly owns 12,000 shares in the company, valued at $540,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the sale, the director now directly owns 12,000 shares in the company, valued at $540,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Asif Ali sold 14,203 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $43.17 on Wednesday. The firm has a 50-day simple moving average of $45.61 and a two-hundred day simple moving average of $38.33. The stock has a market cap of $2.54 billion, a PE ratio of 17.48 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 1-year low of $15.05 and a 1-year high of $48.89.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PTGX shares. Truist Financial assumed coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 price target for the company. JMP Securities reduced their price target on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. TD Cowen raised shares of Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. BTIG Research raised their price objective on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, Wedbush reissued an “outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research note on Monday, November 4th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $53.57.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.